<DOC>
	<DOCNO>NCT00078949</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , dexamethasone , cisplatin , gemcitabine , cytarabine , work different way stop cancer cell divide stop grow die . Combining chemotherapy autologous stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Giving rituximab maintenance therapy stem cell transplantation may kill remain cancer cell . It yet know salvage chemotherapy regimen effective autologous stem cell transplantation treat relapsed refractory non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study salvage chemotherapy use dexamethasone , cisplatin , gemcitabine see well work compare dexamethasone , cisplatin , cytarabine give autologous stem cell transplantation treat patient relapsed refractory aggressive non-Hodgkin 's lymphoma . This trial also study give rituximab maintenance therapy see well work compare therapy stem cell transplantation . Rituximab add salvage treatment arm CD20+ patient protocol amendment 2005 .</brief_summary>
	<brief_title>Comparison Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With Without Maintenance Rituximab Treating Patients With Relapsed Refractory Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Salvage therapy Primary - Compare response rate transplantation rate patient relapse refractory aggressive non-Hodgkin 's lymphoma treat salvage chemotherapy comprise dexamethasone , cisplatin , gemcitabine without rituximab vs standard platinum-based regimen ( dexamethasone , cisplatin , high-dose cytarabine without rituximab ) . - To compare transplantation rate two protocol salvage regimen . Secondary - Compare event-free overall survival patient treat regimen . - Compare success rate regimen , term get patient autologous stem cell transplantation successful mobilization high-dose chemotherapy . - Compare quality life patient treated salvage regimen . - Compare toxic effect salvage regimens patient . - Compare resource utilization patient treat salvage regimen . - Compare relative medical societal cost salvage regimen outcomes patient . Maintenance therapy Primary - Compare 2-year event-free survival patient CD20+ B-cell lymphoma treat maintenance rituximab salvage regimens autologous stem cell transplantation patient receive treatment . Secondary - Compare 2-year survival patient treat without maintenance rituximab . - Compare toxic effect rituximab vs observation alone patient . OUTLINE : This randomize , multicenter study . For salvage therapy , patient stratify accord participate center , International Prognostic Index score relapse/study entry ( 0 1 v 2 v ≥ 3 ) , immunophenotype ( B cell v T cell ) , response response duration initial chemotherapy ( response progressive disease v &gt; 1 year v ≤ 1 year ) , prior rituximab ( yes v ) . For maintenance therapy , patient stratify accord participate center , salvage therapy treatment randomization ( without rituximab , cisplatin , dexamethasone , gemcitabine v without rituximab , cisplatin , dexamethasone , cytarabine ) , response salvage therapy ( complete response [ CR ] CR unconfirmed [ CRu ] vs partial response [ PR ] v stable disease [ SD ] ) , prior rituximab ( yes v ) . - Salvage therapy : Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV 60 minute day 1 , dexamethasone IV orally day 1-4 , gemcitabine IV 30 minute day 1 8 . Patients CD20+ B cell lymphoma receive rituximab IV 1.5-6 hour day 1 . - Arm II : Patients receive cisplatin IV 24 hour day 1 , dexamethasone arm I , cytarabine IV 3 hour every 12 hour total 2 dos day 2 . Patients CD20+ B cell lymphoma receive rituximab IV 1.5-6 hour day 1 . In arm , treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Patients reassess 2 course . Patients progressive disease remove study . Patients CR , CRu , PR proceed autologous stem cell transplantation ( ASCT ) . Patients SD may proceed ASCT receive 1 additional course salvage therapy discretion investigator . Patients receive additional course salvage therapy reassess completion therapy . Patients progressive disease remove study . Patients PR proceed ASCT . Patients SD may proceed ASCT follow study discretion investigator . - ASCT : Responding patient ( stable disease , center 's policy ) undergo mobilization , stem cell harvest , subsequent ASCT . Patients CD20+ B-cell disease randomize maintenance therapy observation . - Maintenance therapy : Patients randomize 1 2 treatment arm . - Arm I : Beginning day 28 posttransplantation , patient receive rituximab IV every 2 month 6 dos ( total 12 month ) absence disease progression unacceptable toxicity . - Arm II : Patients undergo observation . Quality life assess baseline , day 1 10 course 2 , day 1 course 3 ( give ) , last day salvage therapy ( first day mobilization , give ) , 1 month posttransplantation . Patients undergo ASCT follow month 1 , 3 , 7 , 13 , 19 , 25 annually thereafter . Patients complete salvage therapy , undergo ASCT follow month 4 , 8 , 14 , 20 , 26 annually thereafter . Patients relapse progress follow every 6 month 25 month ASCT 26 month completion salvage therapy annually thereafter . PROJECTED ACCRUAL : A total 637 patient accrue study within 3-4 year first randomization , 240 transplant CD20+ patient need second randomization .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma 1 follow subtypes : Diffuse large cell lymphoma ( include primary mediastinal Bcell lymphoma Tcellrich Bcell lymphoma ) Prior indolent lymphoma ( e.g. , follicular center cell lymphoma ; marginal zone lymphoma , include extranodal mucosaassociated lymphoid tissue [ MALT ] lymphoma ; lymphoplasmacytoid lymphoma ) transformation diffuse large Bcell lymphoma relapse Must histologically confirm No transform lymphoma diagnosis subsequent indolent histology without transformation relapse Peripheral Tcell lymphoma Anaplastic large cell lymphoma Small noncleaved Burkittlike lymphoma Tcell Bcell lineage confirm immunohistochemistry Clinically radiologically document disease meeting either follow criterion : Measurable disease , define least 1 bidimensionally measurable site disease use clinical exam , CT scan , MRI Lymph node must &gt; 1.5 cm physical exam CT scan Other nonnodal lesion must ≥ 1.0 cm physical exam , CT scan , MRI Bone lesion consider measurable Evaluable disease , define nonmeasurable disease , include follow : Marrow infiltration Cytologyconfirmed ascites effusion Bony involvement Enlarged liver spleen Unidimensionally measurable intrathoracic abdominal mass Previously treat 1 , 1 , chemotherapy regimen include anthracycline exclude cisplatin , cytarabine , gemcitabine No uncontrolled CNS involvement lymphoma No CNS disease time relapse CNS disease diagnose initial presentation allow provide complete response CNS disease achieve maintained PATIENT CHARACTERISTICS : Age 16 65 Performance status ECOG 03 Life expectancy At least 12 week Hematopoietic Absolute granulocyte count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( 5 time ULN liver involvement lymphoma ) Hepatitis B status know ( patient history hepatitis B high risk hepatitis B infection ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No significant cardiac dysfunction cardiovascular disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing complete quality life questionnaire HIV negative No active , uncontrolled bacterial , fungal , viral infection No malignancy within past 5 year except adequately treat basal cell skin cancer carcinoma situ cervix No concurrent serious illness medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy Prior rituximab allow Chemotherapy See Disease Characteristics At least 4 week since prior IV chemotherapy No prior highdose chemotherapy stem cell transplantation Endocrine therapy No concurrent corticosteroid except physiologic replacement Radiotherapy At least 4 week since prior radiotherapy recover Exceptions may make lowdose , nonmyelosuppressive radiotherapy No prior radiotherapy 25 % function bone marrow Involvedfield radiotherapy may give area bulky disease relapse ( ≥ 5 cm ) stem cell transplantation , accord center 's policy Surgery At least 2 week since prior major surgery Other No concurrent anticancer therapy No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
</DOC>